Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Abstract Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Re...

Full description

Bibliographic Details
Main Authors: Mayte Delgado-Ureña, Francisco G. Ortega, Diego de Miguel-Pérez, Alba Rodriguez-Martínez, Jose L. García-Puche, Hugh Ilyine, Jose A. Lorente, Jose Exposito-Hernandez, M. Carmen Garrido-Navas, Miguel Delgado-Ramirez, M. José Serrano
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Journal of Translational Medicine
Subjects:
Metastatic colorectal cancer
Bevacizumab
Circulating tumor cells
RECIST
CyCAR
Prognosis
Online Access:http://link.springer.com/article/10.1186/s12967-018-1624-2

Internet

http://link.springer.com/article/10.1186/s12967-018-1624-2

Similar Items